From Big Data, to Real World Evidence to Value Proposition and Reimbursements, regulators and sponsors must guide new pharma product development and promotion to be consistent with product labeling as the regulatory approval environment becomes more complex. Read on in ISPE’s iSpeak blog written by EAS independent consultant, John Harbell.
Posted in EAS in Action, EASeNews.